Expert Opinion on Drug Discovery

Scope & Guideline

Fostering Collaboration for Breakthrough Discoveries

Introduction

Explore the comprehensive scope of Expert Opinion on Drug Discovery through our detailed guidelines, including its aims and scope. Stay updated with trending and emerging topics, and delve into declining areas to understand shifts in academic interest. Our guidelines also showcase highly cited topics, featuring influential research making a significant impact. Additionally, discover the latest published papers and those with high citation counts, offering a snapshot of current scholarly conversations. Use these guidelines to explore Expert Opinion on Drug Discovery in depth and align your research initiatives with current academic trends.
LanguageEnglish
ISSN1746-0441
PublisherTAYLOR & FRANCIS LTD
Support Open AccessNo
CountryUnited Kingdom
TypeJournal
Convergefrom 2006 to 2024
AbbreviationEXPERT OPIN DRUG DIS / Expert. Opin. Drug Discov.
Frequency6 issues/year
Time To First Decision-
Time To Acceptance-
Acceptance Rate-
Home Page-
Address2-4 PARK SQUARE, MILTON PARK, ABINGDON OR14 4RN, OXON, ENGLAND

Aims and Scopes

The journal 'Expert Opinion on Drug Discovery' focuses on providing insights and reviews related to the methodologies and advancements in drug discovery and development. It aims to address various challenges in the field and explore new frontiers that can lead to innovative therapeutic solutions.
  1. Innovative Drug Discovery Strategies:
    The journal emphasizes novel approaches in drug discovery, including the use of artificial intelligence, machine learning, and computational methods to enhance the efficiency and accuracy of drug design.
  2. Targeted Therapeutics Development:
    It covers research aimed at developing drugs targeting specific diseases, particularly in oncology, neurology, and infectious diseases, highlighting the importance of understanding disease mechanisms.
  3. Repurposing Existing Drugs:
    The journal explores strategies for repurposing existing drugs for new therapeutic uses, especially in the context of emerging health crises such as COVID-19.
  4. Translational Research:
    There is a strong focus on bridging the gap between preclinical studies and clinical applications, emphasizing the relevance of animal models and in vitro systems in drug discovery.
  5. Emerging Technologies in Drug Discovery:
    The journal discusses advancements in technologies such as high-throughput screening, nanotechnology, and 3D cell culture models, which are pivotal for modern drug discovery.
  6. Challenges in Drug Development:
    It addresses the various challenges faced in drug development, including issues of bioavailability, drug resistance, and regulatory hurdles.
The journal has seen a significant increase in interest in several emerging themes that reflect the forefront of drug discovery research. These trends indicate a shift towards more integrated and technology-driven approaches.
  1. Artificial Intelligence and Machine Learning:
    There is a growing emphasis on the application of AI and machine learning in drug discovery, focusing on their potential to accelerate the identification and optimization of drug candidates.
  2. Complex Disease Models:
    Research on complex disease models, including polygenic and multifactorial diseases, is trending as scientists seek to better mimic human disease in preclinical settings.
  3. Biologics and RNA-based Therapeutics:
    The exploration of biologics, including monoclonal antibodies and RNA-targeted therapies, has gained traction as a promising area for innovative drug development.
  4. Personalized Medicine Approaches:
    There is an emerging focus on personalized medicine, tailoring drug discovery and development processes to individual patient profiles and genetic backgrounds.
  5. Sustainable and Ethical Drug Discovery:
    Research addressing the ethical implications and sustainability of drug discovery processes, including the use of natural products and environmentally friendly methodologies, is increasingly prominent.

Declining or Waning

While 'Expert Opinion on Drug Discovery' continues to evolve, certain themes have become less prominent in recent publications, reflecting shifts in research focus and emerging methodologies.
  1. Traditional Drug Discovery Techniques:
    There has been a noticeable decline in papers focusing solely on traditional drug discovery methods, as the field increasingly adopts advanced technologies and computational approaches.
  2. General Discussions on Drug Discovery:
    Papers that provide general overviews without a specific focus on innovative methodologies or case studies are becoming less frequent, as the journal seeks to present more targeted and impactful research.
  3. Single Target Drug Discovery:
    The trend towards polypharmacology and multi-target strategies indicates a waning interest in developing drugs that target single pathways or receptors, reflecting a more complex understanding of disease mechanisms.

Similar Journals

Pharmaceutical Sciences

Bridging research and practice to transform healthcare.
Publisher: TABRIZ UNIV MEDICAL SCIENCES, FAC PHARMACYISSN: 1735-403XFrequency: 4 issues/year

Pharmaceutical Sciences, an esteemed journal published by Tabriz University of Medical Sciences, Faculty of Pharmacy, serves as a crucial platform for the dissemination of pioneering research in the fields of pharmaceutical science, pharmacology, and toxicology. With an impact factor reflective of its substantial contribution to the scientific community, this open access journal has been accessible since 2012, ensuring that researchers, professionals, and students worldwide can engage with its rich content. Located in Iran, it has continually evolved, covering research from 2009 to 2024, and boasts impressive rankings in multiple Scopus categories, including Q3 in Pharmaceutical Science and Q2 in Pharmacology, Toxicology and Pharmaceutics. By bridging gaps between scientific inquiry and practical applications, Pharmaceutical Sciences is dedicated to advancing pharmaceutical knowledge and promoting innovative practices that address significant health challenges.

Pharmaceuticals

Transforming Ideas into Breakthroughs in Drug Development
Publisher: MDPIISSN: Frequency: 12 issues/year

Ph pharmaceuticals is a leading peer-reviewed journal published by MDPI, focused on the dynamic fields of pharmaceutical science, drug discovery, and molecular medicine. Since its inception, the journal has established itself as a vital resource for researchers and practitioners, boasting an impressive impact factor reflected in its Q1 and Q2 quartile rankings across multiple categories, including Pharmaceutical Science and Drug Discovery. As an open access journal since 2009, Pharmaceuticals promotes the dissemination of cutting-edge research and innovative findings globally, facilitating collaboration and knowledge sharing among scientists. With a robust ranking in Scopus, specifically at Rank #56 in Pharmaceutical Science and Rank #65 in Drug Discovery, the journal serves as a critical platform for advancing the field and supporting future developments in therapeutics and pharmaceuticals. Based in Switzerland, Pharmaceuticals continues to inspire a diverse readership of scholars and healthcare professionals who are dedicated to improving health outcomes through innovative research.

DRUG DISCOVERY TODAY

Advancing the Frontiers of Drug Discovery
Publisher: ELSEVIER SCI LTDISSN: 1359-6446Frequency: 12 issues/year

DRUG DISCOVERY TODAY is a premier journal published by Elsevier Science Ltd, providing a vital platform for researchers, professionals, and students dedicated to the fields of drug discovery and pharmacology. With the ISSN 1359-6446 and E-ISSN 1878-5832, this esteemed journal has positioned itself at the forefront of scientific literature since its inception in 1996, boasting an impressive convergence set to last until 2024. Recognized for its rigorous peer-review process and high-quality publications, DRUG DISCOVERY TODAY attained a prestigious Q1 ranking in both Drug Discovery and Pharmacology categories for 2023, reflecting its significant impact and relevance in the field. With Scopus rankings placing it within the top percentile, at ranks #9 in Drug Discovery and #17 in Pharmacology out of over 300 journals, this journal serves as a crucial resource for the latest advancements and innovations in drug development. Although it does not offer Open Access, its comprehensive scope encompasses the most recent research, reviews, and insights, making DRUG DISCOVERY TODAY an essential read for anyone seeking to advance their knowledge and practice in pharmaceutical sciences.

EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY

Exploring New Horizons in Bioactive Compound Design.
Publisher: ELSEVIER FRANCE-EDITIONS SCIENTIFIQUES MEDICALES ELSEVIERISSN: 0223-5234Frequency: 18 issues/year

European Journal of Medicinal Chemistry, a premier publication by Elsevier France-Editions Scientifiques Médicales Elsevier, has been at the forefront of advancing medicinal chemistry since its inception in 1974. With an impressive impact factor and ranking in the Q1 quartile across multiple categories including Drug Discovery, Medicine (miscellaneous), Organic Chemistry, and Pharmacology, this journal delivers cutting-edge research and reviews that are vital for researchers and professionals in the field. The journal’s scope encompasses the design, synthesis, and evaluation of biological activity of bioactive compounds, making it a critical resource for those looking to innovate in drug development and therapeutic strategies. Although currently not open access, subscribers can benefit from its diverse range of high-quality articles, ensuring the dissemination of knowledge in the ever-evolving landscape of medicinal chemistry. The European Journal of Medicinal Chemistry continues to play a pivotal role in shaping the future of pharmacological research and its application, thus appealing to an audience dedicated to making impactful scientific contributions.

TRENDS IN PHARMACOLOGICAL SCIENCES

Unveiling Cutting-Edge Trends in Pharmacological Research
Publisher: CELL PRESSISSN: 0165-6147Frequency: 12 issues/year

TRENDS IN PHARMACOLOGICAL SCIENCES, an esteemed journal published by CELL PRESS, is a leading platform in the field of pharmacology and toxicology, with an impressive history since its inception in 1979. With an impact factor that places it in the top quartile category (Q1) for both pharmacology and toxicology as of 2023, it is recognized for disseminating high-quality, peer-reviewed research that shapes the future of these disciplines. The journal is indexed with a robust standing in Scopus rankings, positioned at rank #2 in Toxicology and #6 in Pharmacology, both boasting an extraordinary percentile of 98. Researchers, professionals, and students benefit from its comprehensive coverage, which spans cutting-edge advancements, review articles, and significant trends in drug development and toxicity assessment. While the journal does not currently offer open access options, it remains a vital resource for the academic community, ensuring critical insights into the complexities of pharmacological sciences are readily available to enhance research and practice.

Advances in Pharmacological and Pharmaceutical Sciences

Bridging Research and Practice in Pharmaceutical Sciences.
Publisher: HINDAWI LTDISSN: 2633-4682Frequency: 1 issue/year

Advances in Pharmacological and Pharmaceutical Sciences is a premier open-access journal published by Hindawi Ltd. based in the United Kingdom. Established in 2020, the journal swiftly garnered attention for its commitment to disseminating high-quality research in the realms of pharmacology, toxicology, and pharmaceutical sciences. It holds a commendable impact with notable quartile rankings, including Q2 in both Organic Chemistry and Pharmacology, indicating its importance within these disciplines. By embracing an open-access model, the journal ensures that research findings are widely available, promoting increased visibility and collaboration among researchers, professionals, and students globally. With an ongoing convergence of insights projected through 2024, Advances in Pharmacological and Pharmaceutical Sciences aims to address critical issues and advancements in drug development and therapeutic practices, making it an invaluable resource for those at the forefront of scientific inquiry in pharmacology and related fields.

NATURE REVIEWS DRUG DISCOVERY

Advancing the frontiers of pharmaceutical innovation.
Publisher: NATURE PORTFOLIOISSN: 1474-1776Frequency: 12 issues/year

Nature Reviews Drug Discovery, published by Nature Portfolio, is a premier academic journal dedicated to the field of drug discovery. Since its inception in 2002, this journal has become an essential resource for researchers, professionals, and students, providing high-quality, peer-reviewed articles that present the latest advancements and insights into the complex landscape of pharmaceutical development. With an impressive impact factor placing it in the Q1 category across multiple disciplines, including Drug Discovery and Pharmacology, it continues to lead the way in pharmacological research, evidenced by its top ranks in Scopus among peers. Although it is not an open-access publication, the journal remains a vital tool for those looking to stay abreast of emerging trends and innovations in drug research. For more details about their submission guidelines and access options, visit the official journal website.

Drug Research

Empowering Researchers in the Quest for Innovation
Publisher: GEORG THIEME VERLAG KGISSN: 2194-9379Frequency: 9 issues/year

Drug Research, published by GEORG THIEME VERLAG KG, is a pivotal journal housed in the vibrant realm of pharmacology and drug discovery. With a commitment to advancing the understanding of medicinal substances, this journal serves as an essential resource for researchers, professionals, and students dedicated to the field. The journal boasts an ISSN of 2194-9379 and an E-ISSN of 2194-9387, reflecting its dual commitment to print and digital accessibility. Despite its status as a Q3 journal in both Drug Discovery and Miscellaneous Medicine categories as of 2023, it continues to offer valuable insights with a focus on the latest innovations, methodologies, and findings in drug research. Based in Germany, Drug Research promotes scholarly communication and collaboration within the scientific community, ensuring that its contributions remain impactful in shaping future therapeutic discoveries. The journal is indexed in relevant databases, enhancing its visibility and reach, thus fostering a robust academic dialogue.

Drug Discoveries and Therapeutics

Innovating therapeutics for transformative healthcare.
Publisher: INT RESEARCH & COOPERATION ASSOC BIO & SOCIO-SCIENCES ADVANCEMENTISSN: 1881-7831Frequency: 6 issues/year

Drug Discoveries and Therapeutics is a highly regarded journal devoted to the advancement of knowledge in the field of medicine and pharmacology. Published by the International Research & Cooperation Association for Biological & Socio-Sciences Advancement in Tokyo, Japan, this journal serves as a vital resource for researchers, practitioners, and students interested in the latest developments in drug discovery and therapeutic strategies. With a Scopus ranking of #192 out of 826 in the General Medicine category, and positioning itself in the 76th percentile, it demonstrates a significant impact within the scientific community. The journal publishes original research articles, reviews, and innovative studies that address the complexities of drug development, therapeutic efficacy, and clinical applications. Researchers and clinicians can access valuable insights to enhance their practices and inform further studies as it continues to disseminate crucial findings essential for the advancement of medical science.

MEDICINAL RESEARCH REVIEWS

Driving Excellence in Molecular Medicine Research
Publisher: WILEYISSN: 0198-6325Frequency: 6 issues/year

MEDICINAL RESEARCH REVIEWS, published by Wiley, is a leading journal in the fields of Drug Discovery, Molecular Medicine, and Pharmacology. With an impressive impact factor and esteemed standing in its category quartiles (Q1 in all three fields), this journal serves as a vital platform for the dissemination of cutting-edge research and reviews that drive innovation in therapeutic development and molecular health sciences. Since its inception in 1981, MEDICINAL RESEARCH REVIEWS has garnered a robust readership within the scientific community, underscored by its high rankings in Scopus – where it ranks #3 in Pharmacology and #2 in Drug Discovery, placing it within the top echelons of academic influence. Researchers, professionals, and students alike benefit from its rich content and comprehensive approaches to tackling complex medicinal challenges, making it an essential resource for those invested in advancing the frontiers of biomedical research.